Azera 100 MG 90 Tab

Azera 100Mg 90 Tab Of 1078 Patients Admitted To The Coronary Care Unit With Acute Chest Pain, 293 Who Had Possible Acute Myocardial Infarction And Symptoms Of Median 4 H Duration Were Randomized To Treatment With Azera 100 Mg Daily, 1000 Mg Daily Or Placebo For 3 Months. During Hospitalization, The Combined Incidence Of Cardiac Death And Non-Fatal Myocardial Infarction On-TreatmentWithdrawals Not Included Was Significantly LowerP Less Than 0.02 In The 100 Mg Group7.1% Than In Both The 1000 Mg Group20.8% And The Placebo Group19.7%. During Later Time Periods Of Treatment And At All Time Periods Analysed According To The Intention-To-Treat PrincipleWithdrawals Included, Data Suggested The Same Trend, But Differences Were Not Statistically Significant. Collagen-Induced Platelet Aggregation And Serum Thromboxane B2 Were Reduced To The Same Degree In The Two Asa Groups And Were Normal In The Placebo Group. The Data Suggest That Low-Dose Asa Could Be Cheap And Safe As First-Aid Therapy In Myocardial Infarction Suspects.